SHAREHOLDER NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against KaloBios Pharmaceutic...
2016年1月12日 - 11:10AM
ビジネスワイヤ(英語)
Khang & Khang LLP (the “Firm”) announces that a class action
lawsuit has been filed against KaloBios Pharmaceuticals, Inc.
(“KaloBios” or the “Company”) (Nasdaq: KBIO). Investors who
purchased or otherwise acquired shares between November 19, 2015
and December 17, 2015, inclusive (the “Class Period”) are
encouraged to contact the Firm prior to the February 16, 2016, lead
plaintiff motion deadline.
If you purchased shares of KaloBios during the Class Period,
please contact Joon M. Khang, Esquire, of Khang & Khang, 18101
Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949)
419-3834, or by e-mail at joon@khanglaw.com.
There has been no class certification in this case. Until
certification occurs, you are not represented by an attorney. You
may choose to take no action and remain a passive class member.
According to the complaint, the Company issued materially false
and misleading statements to investors and/or failed to disclose
that: (1) the CEO of KaloBios was engaged in a scheme involving the
illegal use of stock from Retrophin, Inc. to pay off debts
associated with other unrelated business ventures; and (2) the
discovery and revelation of that scheme would likely undermine
KaloBios’ operations and prospects.
If you purchased shares of KaloBios during the Class Period, you
have until February 16, 2016 to ask the Court to appoint you as
lead plaintiff. If you wish to learn more about this
lawsuit, or if you have any questions concerning this notice or
your rights, please contact Joon M. Khang, a prominent litigator
for almost two decades, by telephone: (949) 419-3834, or by e-mail
at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160111006647/en/
KHANG & KHANG LLPJoon M. Khang, Esq.Telephone:
949-419-3834Facsimile: 949-225-4474joon@khanglaw.com
Humanigen (CE) (USOTC:HGEN)
過去 株価チャート
から 7 2024 まで 7 2024
Humanigen (CE) (USOTC:HGEN)
過去 株価チャート
から 7 2023 まで 7 2024